Pemilihan Terapi pada Alopesia Areata
DOI:
https://doi.org/10.18196/mmjkk.v8i2%20(s).1628Keywords:
alopesia areata, imunoterapi, kortikosteroid, terapi, alopecia areata, corticosteroids, therapyAbstract
Alopecia areata (AA) is a chronic inflammatory disease of the hair and nails. This paper will discuss the modalities of therapy and how the selection of therapy in AA. Pathogenesis of AA is still unknown, but it can be ascertained the role of Tlymphocytes, especially CD4 and IFN. Etiopathogenesis factors in AA are genetic, immunological, neurological, emotional stress and abnormality of keratinocytes and melanocytes. Various modalities of therapy are corticosteroids, imunoterapi contacts, phototherapy, minoksidil, antralin/ditranol, or use a wig. Selection of AA treatment modality needs to consider the clinical course, evolution and response to therapy and medication side effects. Based on this, one option of treatment is to let AA. The one choice of treatment of AA without medication is using a wig. While based on research, the most effective therapy for AA is contacts imunotherapy and corticosteroids, but still neededfurther research to determine the dose and how administered.
Alopesia areata (AA) adalah penyakit inflamasi kronis yang mengenai rambut dan kadang- kadang kuku DAN cukup sering terjadi. Patogenesis AA belum diketahui dengan pasti, namun dapat dipastikan peran limfosit T terutama CD4 dan IFNg pada terjadinya AA. Faktor etiopatogenesis pada AA adalah genetik, imunologi, neurologi, stres emosional dan abnormalitas keratinosit dan melanosit. Makalah ini akan membahas modalitas terapi dan cara pemilihan terapi pada AA. Berbagai modalitas terapi yang tersedia untuk AA adalah kortikosteroid, imunoterapi kontak, fototerapi, minoksidil, antralin/ditranol, maupun pemakaian rambut palsu. Pemilihan modalitas terapi AA perlu mempertimbangkan perjalanan klinis, evolusi dan respon terapi serta efek samping pengobatan. Berdasar hal ini, salah satu pilihan penanganan AA adalah membiarkan AA tanpa pengobatan atau menggunakan rambut palsu. Sedangkan berdasar penelitian yang ada, terapi yang paling efektif untuk AA adalah imunoterapi kontak dan kortikosteroid, namun masih diperlukan penelitian lebih lanjut untuk menentukan dosis maupun cara pemberiannya.
References
MacDonald Hull SP, Wood ML, Hutchinson PE, Ladden MS, Messenger AG, Guidelines for the management of alopecia areata. Br J Dermatol, 2003, 149: 692-99.
Mitchell AJ dan Krull EA, Alopecia areata: Pathogenesis and treatment, J Am Acad Dermatol.1984, 11: 763-75.
Madani S dan Shapiro J, Alopecia areata update, J Am Acad Dermatol. 2000, 42: 549-66.
Olsen EA, Hair disorder, dalam Freedberg I.M., Eisen A.Z., Wolff K., Austen K.F.. Dermatology in General Medicine, 5th ed. New York, Mc Graw- Hill Inc. 1999 : 729-50.
Freyschmidt-Paul P, Happle R, McElwee J, Hoffmann R, Alopecia areata: treatment of today and tomorrow, JID Symposium Proceedings., 2003, 8: 12-17.
Gulec AT, Tanriverdi N, Durii C, Saray Y, Akcah C. The role of psychological factors in alopecia areata and the impact of the disease on the quality of life. Int J Dermatol, 2004, 43: 352-6.
Paus R dan Cotsarelis G. The biology of hair follicles. New England J Medicine, 1999, 341(7): 491-7.
Dawber RPR, The hair follicle structure, keratinization and physical properties of hair. dalam Rook A and Dawber R. Diseases of the hair and scalp, 2 ed. Oxford, Blacwell scientific publications, 1991: 18-40.
Harrison S dan Sinclair R. Telogen Effluvium. Clin Dermatol, 2002, 27: 389¬95.
Kalish RS dan Gilhar A, The immunology of alopecia areata and potential application to novel therapy, Dermathologic Therapy. 2001, 14: 322-28.
Price VH dan Colombe BW, Heritable factors distinguish two types of alopecia areata, Dermatol Clinic.1996, 14: 679-89 (abstrak).
Simpson NB, Alopecia areata, dalam Rook A and Dawber R. Diseases of the hair and scalp, 2 ed. Oxford, Blacwell scientific publications, 1991: 296-330.
Meyronet D, Jaber K, Gentil-Perret A, Cambazard F, Misery L. Decreased CGRP staining in alopecia areata. B J Dermatol, 2003, 149: 422-23.
Buldoc C dan Shapiro J, The traetment of alopecia areata. Dermatologic Therapy, 2001, 14: 306-16.
Wolverton SE. Systemic corticosteroid. dalam Wolverton SE, Comprehensive Dermatologic Drug Therapy (Ed. Wolverton, SE.), WB Saunders Company, 2001, 109-42.
Charuwichitratana S, Wattanakrai P, Tanrattanakorn S. Randomized-double blind placebo-controlled trial in the treatment of alopecia areata with 0,25% desoximethason cream. Arch Dermatol, 2000, 136: 1276-7 (abstrak).
Kar BR, Handa S, Dogra S, Kumar B. Placebo-controlled oral pulse prednisolone therapy in alopecia areata. J Am acad Dermatol, 2005, 52: 287-90.
van der Steen PH, Baar HM, Happle R dkk. Prognostic factor in the treatment of alopecia areata with diphenylcyclopropenone. J Am Acad Dermatol, 1991,24: 227-30.
Rokhsar CK, Shupack JL, Vafai JJ, dkk. Efficacy of topical sensitizers in the treatment of alopecia areata, J Am Acad Dermatol. 1998, 39:751-61.
Hchuttelaar ML, Hamstra JJ, Plinck EP dkk. Alopecia areata in childre: response to the treatment of diphencyprone, Br J Dermatol, 1996, 135: 581-5.
Alam M, Gross EA, savin RC. Severe urticaria during topical immunotherapy for alopecia areata, J Am Acad Dermatol. 1999, 40:110-12.
Henderson CA, Ilchyshyn A, Vitiligo complicating diphencyprone sensitization therapy for alopecia universalis, Br J Dermatol. 1995, 133:496-7.
Hoffmann R, Happle R. Topical immunotherapy in alopecia areata: what, how and why? Dermatol Clin, 1996, 14: 739-44.
Taylor CR, Hawk JL, PUVA treatment of alopecia areata partialis, totalis and ubiversalis: audit of 10 years experience at St John’s Institute of dermatology. Br J Dermatol, 1995, 133: 914-18.
Price VH. Double-blind placebo- controlled evaluation of topical minoxidil in extensive alopecia areata. J Am Acad Dermatol. 1987, 16:730-36.
Shapiro J, Lui H, Tron V, dkk. Systemic cyclosporin and low dose prednisone in the treatment of chronic severe alopecia areata: a clinical and immunopathologic evaluation. J Am Acad Dermatol. 1997, 36:114-17.
Cotellessa C, Peris K, Caracciolo dkk. The use of topical diphenylcycloprophenone for the treatment of extensive alopecia areata, J Am Acad Dermatol, 2001; 44; 73-76. Olsen EA, Hordinsky MK, Price VH, dkk,. Alopecia areata investigational assessment guidelines- part II, J Am Acad Dermatol, 2004; 51; 440-447.
Downloads
Published
Issue
Section
License
Copyright
Authors retain copyright and grant Mutiara Medika: Jurnal Kedokteran dan Kesehatan (MMJKK) the right of first publication with the work simultaneously licensed under an Attribution 4.0 International (CC BY 4.0) that allows others to remix, adapt and build upon the work with an acknowledgment of the work's authorship and of the initial publication in Mutiara Medika: Jurnal Kedokteran dan Kesehatan (MMJKK).
Authors are permitted to copy and redistribute the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in Mutiara Medika: Jurnal Kedokteran dan Kesehatan (MMJKK).
License
Articles published in the Mutiara Medika: Jurnal Kedokteran dan Kesehatan (MMJKK) are licensed under an Attribution 4.0 International (CC BY 4.0) license. You are free to:
- Share — copy and redistribute the material in any medium or format.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
This license is acceptable for Free Cultural Works. The licensor cannot revoke these freedoms as long as you follow the license terms. Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
